Recent News
NASCAR Will Put Fans in Driver’s Seat at Homestead
Tuesday, October 25
PEPTILOGICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B STUDY OF PLG0206 FOR PERIPROSTHETIC JOINT INFECTION
Thursday, October 06
Disrupters: Jonathan Steckbeck
Friday, September 30
Why Pittsburgh biotech company Carmell Therapeutics is going public
Monday, September 12
Why is Carmell Therapeutics, poised to become the newest public company in the Pittsburgh region, taking that big step? CEO Randy Hubbell said it's the right move for the Pittsburgh-based biotech company, which is a spinout of Carnegie Mellon University and is getting ready for the day when its first products will be commercialized.
Read MoreCytoAgents Announces Appointment of New Chief Medical Officer
Wednesday, September 07
WPXI's Our Regions Business Featuring PittMoss
Tuesday, August 09
Peptilogics Receives FDA Fast Track Designation for PLG0206, an Investigational Peptide Therapeutic in Development for the Treatment of Periprosthetic Joint Infection
Monday, July 25
Peptilogics, a biotech company engineering peptide therapeutics to improve the treatment landscape for patients with life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s lead drug candidate, PLG0206, for the treatment of periprosthetic joint infection (PJI).
Read More